Shots:

• Marengo to receive $45M up front & is eligible to receive ~$1.592B upon achievement of milestones along with royalty
• Under the terms of the agreement, Marengo will be responsible for the preclinical development and expense-related costs before submitting an IND application to the US FDA. Ipsen will lead the clinical development and commercialization
• The collaboration will use Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation with Ipsen’s global oncology footprint for the clinical development and commercialization of novel and durable therapies to treat cancer patients

Ref: Bussinesswire | Image: Ipsen